GGrantIndex
← Search

SAFETY/TOLERABILITY OF CGP 77116 IN MULTIPLE SCLEROSIS

$0M01FY2000RRNIH

Yale University, New Haven CT

Investigators

Linked publications & trials

Abstract

This study will evaluate and compare safety, tolerability, and effect on cranial MRI of three dose levels of CGP77116 versus placebo in patients with relapsing-remitting multiple sclerosis. The purpose of the study is to assess whether CGP77116 modifies inflammatory disease activity as measured by MRI and to facilitate dose selection for future studies in relapsing-remitting multiple sclerosis.

View original record on NIH RePORTER →